Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

PhD thesis opposing immunisation: Failure of academic rigour with real-world consequences.

Wiley KE, Leask J, Burgess MA, McIntyre PB.

Vaccine. 2019 Mar 14;37(12):1541-1545. doi: 10.1016/j.vaccine.2018.12.024. No abstract available.

2.

The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.

Sauboin C, Holl K, Bonanni P, Gershon AA, Benninghoff B, Carryn S, Burgess MA, Wutzler P.

BMC Infect Dis. 2019 Feb 6;19(1):126. doi: 10.1186/s12879-019-3759-z.

3.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
4.

Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.

Brown JB, Pai RK, Burgess MA, Chennat J, Zureikat AH.

J Natl Compr Canc Netw. 2018 Dec;16(12):1424-1428. doi: 10.6004/jnccn.2018.7063.

PMID:
30545989
5.

Models of strategies for control of rubella and congenital rubella syndrome-a 40 year experience from Australia.

Gao Z, Wood JG, Burgess MA, Menzies RI, McIntyre PB, MacIntyre CR.

Vaccine. 2013 Jan 11;31(4):691-7. doi: 10.1016/j.vaccine.2012.11.043. Epub 2012 Nov 26.

PMID:
23196206
6.

Estimating distribution of hidden objects with drones: from tennis balls to manatees.

Martin J, Edwards HH, Burgess MA, Percival HF, Fagan DE, Gardner BE, Ortega-Ortiz JG, Ifju PG, Evers BS, Rambo TJ.

PLoS One. 2012;7(6):e38882. doi: 10.1371/journal.pone.0038882. Epub 2012 Jun 25.

7.

Antibody persistence six years after two doses of combined hepatitis A and B vaccine.

Burgess MA, McIntyre PB, Hellard M, Ruff TA, Lefevre I, Bock HL.

Vaccine. 2010 Mar 2;28(10):2222-2226. doi: 10.1016/j.vaccine.2009.12.053. Epub 2010 Jan 5.

PMID:
20056187
8.

Rapid impact of rotavirus vaccination in the United States: implications for Australia.

Macartney KK, Burgess MA.

Med J Aust. 2009 Aug 3;191(3):131-2.

PMID:
19645636
9.

Women and vaccinations: From smallpox to the future, a tribute to a partnership benefiting humanity for over 200 years.

Datta SK, Bhatla N, Burgess MA, Lehtinen M, Bock HL.

Hum Vaccin. 2009 Jul;5(7):450-4. Epub 2009 Jul 20. Review.

PMID:
19458487
10.

More data from Australia on sensitivity to HPV vaccine.

McIntyre PB, Brotherton JM, Burgess MA, Kemp AS.

BMJ. 2009 Jan 9;338:b26. doi: 10.1136/bmj.b26. No abstract available.

PMID:
19136536
11.

Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.

McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B.

Vaccine. 2009 Feb 11;27(7):1062-6. doi: 10.1016/j.vaccine.2008.11.102. Epub 2008 Dec 16.

PMID:
19095033
12.

Congenital rubella and diabetes mellitus.

Burgess MA, Forrest JM.

Diabetologia. 2009 Feb;52(2):369-70; author reply 373. doi: 10.1007/s00125-008-1227-1. Epub 2008 Nov 26. No abstract available.

PMID:
19034414
13.

Anaphylaxis following quadrivalent human papillomavirus vaccination.

Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S; New South Wales Health HPV Adverse Events Panel.

CMAJ. 2008 Sep 9;179(6):525-33. doi: 10.1503/cmaj.080916. Epub 2008 Sep 1.

14.

Varicella vaccination in Australia and New Zealand.

Macartney KK, Burgess MA.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S191-5. doi: 10.1086/522157.

PMID:
18419396
15.

Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement.

DeMartelaere SL, Roberts D, Burgess MA, Morrison WH, Pisters PW, Sturgis EM, Ho V, Esmaeli B.

Head Neck. 2008 May;30(5):639-46. doi: 10.1002/hed.20757.

PMID:
18213722
16.

We should desist using RECIST, at least in GIST.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C.

J Clin Oncol. 2007 May 1;25(13):1760-4.

PMID:
17470866
17.
18.

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.

Ann Surg Oncol. 2007 Jan;14(1):14-24.

PMID:
17072676
19.
20.

Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future.

Salmon DA, Teret SP, MacIntyre CR, Salisbury D, Burgess MA, Halsey NA.

Lancet. 2006 Feb 4;367(9508):436-42. Review.

PMID:
16458770
21.

Varicella vaccination in Australia.

Macartney KK, Beutels P, McIntyre P, Burgess MA.

J Paediatr Child Health. 2005 Nov;41(11):544-52. Review.

PMID:
16398834
22.

Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia.

Gidding HF, Brisson M, Macintyre CR, Burgess MA.

Aust N Z J Public Health. 2005 Dec;29(6):544-51.

PMID:
16366065
23.

Immunity to diphtheria and tetanus in Australia: a national serosurvey.

Gidding HF, Backhouse JL, Burgess MA, Gilbert GL.

Med J Aust. 2005 Sep 19;183(6):301-4.

PMID:
16167869
24.

Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia.

Brotherton JM, Hull BP, Hayen A, Gidding HF, Burgess MA.

Pediatrics. 2005 Jun;115(6):e643-6.

PMID:
15930190
25.

National serosurvey of poliovirus immunity in Australia, 1996-99.

Gidding HF, Backhouse JL, Gilbert GL, Burgess MA.

Aust N Z J Public Health. 2005 Feb;29(1):48-52.

PMID:
15782872
26.

Prevalence and determinants of influenza vaccination in Australians aged 40 years and over--a national survey.

Horby PW, Williams A, Burgess MA, Wang H.

Aust N Z J Public Health. 2005 Feb;29(1):35-7.

PMID:
15782869
27.

Influenza A associated morbidity and mortality in a Paediatric Intensive Care Unit.

Milne BG, Williams S, May ML, Kesson AM, Gillis J, Burgess MA.

Commun Dis Intell Q Rep. 2004;28(4):504-9.

28.

High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.

McIntyre PB, Turnbull FM, Egan AM, Burgess MA, Wolter JM, Schuerman LM.

Vaccine. 2004 Dec 2;23(3):380-5.

PMID:
15530684
29.

Age-related risk of adverse events following yellow fever vaccination in Australia.

Lawrence GL, Burgess MA, Kass RB.

Commun Dis Intell Q Rep. 2004;28(2):244-8. Erratum in: Commun Dis Intell. 2004;28(3):348.

30.

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML.

Cancer Res. 2004 Sep 1;64(17):5913-9.

31.

Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.

Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT.

J Clin Oncol. 2004 Aug 15;22(16):3375-80.

PMID:
15310783
32.

Vaccines: the new Australian best-practice schedule.

Burgess MA, McIntyre PB.

Med J Aust. 2004 May 17;180(10):494-6. No abstract available.

PMID:
15139824
33.

The seroepidemiology and transmission dynamics of varicella in Australia.

Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL.

Epidemiol Infect. 2003 Dec;131(3):1085-9.

34.

Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW.

Am J Surg. 2003 Dec;186(6):665-9.

PMID:
14672776
35.

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR.

Cancer. 2003 Dec 15;98(12):2693-9.

37.

Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.

Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR.

J Clin Oncol. 2003 Aug 15;21(16):3092-7.

PMID:
12915599
38.

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.

Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS.

Cancer. 2003 Jun 1;97(11):2848-52.

39.

Hepatitis A vaccination options for Australia.

MacIntyre CR, Burgess MA, Hull B, McIntyre PB.

J Paediatr Child Health. 2003 Mar;39(2):83-7. Review.

PMID:
12603793
40.

Gregg's congenital rubella patients 60 years later.

Forrest JM, Turnbull FM, Sholler GF, Hawker RE, Martin FJ, Doran TT, Burgess MA.

Med J Aust. 2002 Dec 2-16;177(11-12):664-7.

PMID:
12463994
41.

Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas.

Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW.

Cancer. 2002 Sep 1;95(5):1120-6.

42.

Tumor volume as a prognostic factor for sarcomatosis.

Bilimoria MM, Holtz DJ, Mirza NQ, Feig BW, Pisters PW, Patel S, Pollock RE, Benjamin RS, Papadopoulos NE, Plager C, Murphy A, Griffin JR, Burgess MA, Hunt KK.

Cancer. 2002 May 1;94(9):2441-6.

43.

National study of adverse reactions after vaccination with bacille Calmette-Guérin.

Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, Burgess MA.

Clin Infect Dis. 2002 Feb 15;34(4):447-53. Epub 2002 Jan 4.

PMID:
11797170
44.

Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.

Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, Pisters PW.

Cancer. 2001 Sep 15;92(6):1550-5. Review.

PMID:
11745234
45.

Impact of the Australian Measles Control Campaign on immunity to measles and rubella.

Gilbert GL, Escott RG, Gidding HF, Turnbull FM, Heath TC, McIntyre PB, Burgess MA.

Epidemiol Infect. 2001 Oct;127(2):297-303.

46.

The Australian Measles Control Campaign, 1998.

Turnbull FM, Burgess MA, McIntyre PB, Lambert SB, Gilbert GL, Gidding HF, Escott RG, Achat HM, Hull BP, Wang H, Sam GA, Mead CL.

Bull World Health Organ. 2001;79(9):882-8. Epub 2001 Oct 23.

47.

Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas.

Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS.

Cancer. 2001 Sep 1;92(5):1347-8. No abstract available.

PMID:
11571751
49.

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.

Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS.

J Clin Oncol. 2001 Aug 1;19(15):3483-9.

PMID:
11481354
50.

Hepatitis A epidemiology in Australia: national seroprevalence and notifications.

Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA.

Med J Aust. 2001 Apr 2;174(7):338-41.

PMID:
11346106

Supplemental Content

Loading ...
Support Center